Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Nat Rev Drug Discov
.
2022 Jul;21(7):482-483.
doi: 10.1038/d41573-022-00030-4.
Authors
Samik Upadhaya
,
Svetoslav T Neftelinov
,
Jeffrey Hodge
,
Jay Campbell
PMID:
35145263
DOI:
10.1038/d41573-022-00030-4
No abstract available
MeSH terms
B7-H1 Antigen*
Clinical Trials as Topic
Humans
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor*
Substances
B7-H1 Antigen
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor